Study guide
15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples
NCRA Oncology Data Specialist ODS-C
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters
1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish
2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws
2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority
3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance
3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance
4 Chapter 4: Registry Organization, Staffing & Information Systems
4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning
5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement
5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)
6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality
6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)
7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics
7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data
8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer
8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors
9 Chapter 9: Casefinding & Reportability
9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"
10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators
10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More
11 Chapter 11: Class of Case, Key Dates & Case Identifiers
11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them
12 Chapter 12: Follow-Up, Vital Status & Recurrence
12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary
13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade
13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables
14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules
14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules
15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018
15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples
16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS
16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation
15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples
Key Takeaways Explain This Topic AI
SS2018 codes are 0 in situ, 1 localized, 2 regional by direct extension only, 3 regional lymph nodes only, 4 regional by both, 7 distant, 8 benign or borderline (brain and CNS chapters only), and 9 unknown.
Summary Stage includes all information within four months of diagnosis without disease progression, or through completion of first-course surgery, whichever is longer; progression after the initial workup is excluded.
Tumor size does not affect Summary Stage, unknown lymph node status is treated as no involvement, and positive regional nodes (Regional Nodes Positive 01–90, 95, 97) require code 3, 4 or 7.
After neoadjuvant treatment, surgical findings are used only if they show more extensive disease than the pre-treatment clinical findings.
Death certificate only cases and unknown primaries (C809) are always 9; melanoma in-transit, satellite and microsatellite metastases count as positive nodes (code 3); leukemias and plasma cell myeloma are 7.
Last updated: September 2026
Why Summary Stage exists
Summary Stage is the simplest way to compare stage across all cancers, across time, and between hospital and population registries. It is based on anatomic extent only and applies to every primary site and histology . Many chapters are defined by site, some by histology, and some by both. SS2018 chapters follow AJCC 8th edition concepts and, from 2021, the AJCC Version 9 updates, but the two systems differ . Something regional in AJCC can be distant in Summary Stage. If a structure or node is not listed under codes 1–4, check code 7.
The codes
- Code Meaning
- 0 In situ, intraepithelial, noninvasive
- 1 Localized only (confined to the organ of origin)
- 2 Regional by direct extension only
- 3 Regional lymph node(s) only
- 4 Regional by both direct extension and lymph nodes (2 + 3)
- 7 Distant site(s) or distant lymph node(s)
- 8 Benign or borderline: only for the Brain, CNS Other, Intracranial Gland and (2023+) Medulloblastoma chapters
- 9 Unknown if extension or metastasis (unstaged)
The code is hierarchical : when more than one applies, use the highest .
Time frame
"Summary Stage should include all information available within four months of diagnosis in the absence of disease progression or upon completion of surgery(ies) in first course of treatment , whichever is longer ."
Disease progression , including metastases, known to have developed after the initial staging workup is excluded.
General rules
Combined assessment: code from clinical and operative or pathological information together. Gross findings at surgery matter when tumor cannot be removed. If the pathology and operative reports disagree about excised tissue, the pathology report has priority. If the pathology disproves a clinical finding, use the pathology.
Tumor size does not affect Summary Stage. For most chapters, SSDIs do not either.
Unknown primary extent: if regional nodes are positive but the primary's extent is unknown, default to 3 . If distant metastasis is present, default to 7 .
In situ primary with positive nodes or metastases: code 3 or 7. The behavior becomes /3, because an invasive component must exist.
Unknown node status is treated as "none." If there is no information on distant metastasis, assume there is none.
Regional Nodes Positive coded 01–90, 95 or 97 means nodes are involved, so Summary Stage must be 3, 4 or 7 .
Multiple tumors abstracted as one primary: assign the greatest stage from any tumor.
Neoadjuvant therapy: use surgical findings after neoadjuvant treatment only if the extent is greater than the pre-treatment clinical findings. Otherwise use the clinical findings.
Autopsy reports are used like pathology reports.
TNM only: T, N and M information may be used when it is the only information. If TNM and the medical record disagree, use the record, and query the physician if possible.
Chapter-specific instructions override the general instructions.
Code 9 rules
Unknown primary (C809) must be coded 9.
Death certificate only cases are always 9, even for histologies with a default stage. The manual's example: AML known only from a death certificate is 9, not 7.
Use 9 sparingly. Typical reasons are death before workup, refusal of diagnostic procedures, a limited workup, or a biopsy that alone cannot show extent.
Code 8 rules
Code 8 is only for benign or borderline tumors in the brain and CNS chapters, such as meningioma 9530/0 or vestibular schwannoma 9560/0.
If a registry collects other non-reportable benign or borderline tumors, Summary Stage is 9 , not 8.
- High-yield chapters
- Cutaneous melanoma
- Code Examples
- 0 Melanoma in situ
- 1 Confined to the dermis, or through the dermis into subcutaneous tissue
- 2 Direct extension into bone, cartilage, fascia or skeletal muscle
3 Regional lymph nodes , including isolated tumor cells, and in-transit, satellite or microsatellite metastases , with or without regional nodes (they are counted as positive nodes)
- 4 Codes 2 + 3
- 7 Distant sites or distant nodes
Breslow thickness and ulceration change the AJCC T category but not Summary Stage. For example, a 6.0 mm ulcerated melanoma with no spread is 1 .
Lymphoma
Codes 0, 3 and 4 are not used.
Code Nodal lymphomas Extranodal lymphomas
1 A single lymph node region, including several chains in the same region A single extralymphatic site without nodes
2 Two or more node regions on the same side of the diaphragm A single extralymphatic site with its regional nodes, or other nodes on the same side of the diaphragm
7 Node regions on both sides of the diaphragm; nodes above the diaphragm plus spleen Diffuse or disseminated organ involvement; bone marrow, peripheral blood, CSF, liver , or lung (other than direct extension); bilateral paired organs (for example, both eyes)
Lymph node descriptions such as "enlarged," "shotty," "matted" or "lymphadenopathy" count as involvement for lymphoma.
Myeloma and other heme neoplasms
Plasma cell myeloma (9732) is always 7 . So are lymphoplasmacytic lymphoma (9671) and Waldenström macroglobulinemia (9761).
A single plasmacytoma of bone (9731) or outside bone (9734) is 1 . An extraosseous plasmacytoma with regional nodes is 3 .
Leukemias and most myeloid neoplasms are 7 , using the "Hemeretic" chapter. A few histologies, such as myeloid sarcoma and histiocytic sarcoma, can be 1 , 7 or 9 .
Crosswalk examples
- Case Summary Stage
- DCIS with microinvasion of 1 mm, nodes negative 1
- Colon adenocarcinoma into the submucosa, 0/14 nodes 1
Colon adenocarcinoma invading subserosal fat , 0/16 nodes (AJCC pT3) 1 : the colon chapter lists subserosal tissue under localized
Sigmoid adenocarcinoma invading "pericolonic tissue," 0/16 nodes 2 : the sigmoid is entirely peritonealized, so pericolonic tissue invasion there is regional
- Breast 1.8 cm, 2 of 12 axillary nodes positive 3
- Lung primary with a biopsy-proven brain metastasis 7
- Acute myeloid leukemia on bone marrow biopsy 7
- AML known only from a death certificate 9
- Benign meningioma 8